<DOC>
	<DOCNO>NCT00526136</DOCNO>
	<brief_summary>To evaluate safety , tolerability efficacy 3 dos vernakalant ( oral ) ( 150 mg , 300 mg 500 mg b.i.d . ) administer 90 day subject sustain symptomatic atrial fibrillation ( AF duration &gt; 72 hour &lt; 6 month ) .</brief_summary>
	<brief_title>Vernakalant ( Oral ) Prevention Atrial Fibrillation Recurrence Post-Conversion Study</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Comprehend sign write informed consent form , ( per local national regulation , applicable ) Be 18 85 year age Women must pregnant , nonnursing premenopausal , must use effective form birth control time screen 3 month last dose medication . Methods birth control consider effective may include hormonal contraception ( pill ) , intrauterine device ( IUD ) , condoms combination spermicidal cream , total abstinence sterilisation . Men advise conceive child advise use effective form birth control admission 3 month last dose study medication Have symptomatic AF sustain great 72 hour less 6 month duration clinically indicated cardioversion ; Have adequate anticoagulant therapy cardioversion accordance standard practice recommend ACC/AHA/ESC guideline ( Fuster V. et al , 2006 ) ; Be haemodynamically stable ( 100 mmHg &lt; systolic blood pressure &lt; 190 mmHg ) screen Day 1 dosing ( take rate control drug , require ) . After rest supine 3 minute , blood pressure measure 3 time 5 minute least 1 minute assessment ; Have body weight 45 113 kg ( 99 250 lb ) . Have know prolonged QT syndrome QTcB interval &gt; 0.500 sec measure screen 12 lead ECG ; familial long QT syndrome ; previous Torsades de Pointes ; ventricular fibrillation ; sustain ventricular tachycardia ( VT ) . Have QRS &gt; 0.140 sec ; Documented previous episode second thirddegree atrioventricular block ; Have clinically significant persistent bradycardia ventricular rate 50 beats/min , sicksinus syndrome pacemaker ; Have clinically significant moderate severe aortic valvular stenosis ( gradient &gt; 25 mmHg ) , hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy constrictive pericarditis ; Have Class III Class IV congestive heart failure screen admission , hospitalize heart failure previous 6 month ; Have myocardial infarction ( MI ) , cardiac surgery , angioplasty , unstable angina acute coronary syndrome within 30 day prior entry study ; h ) Have serious pulmonary , hepatic , metabolic , renal ( serum creatinine &gt; 2.0 mg/dl ) , gastrointestinal , central nervous system ( CNS ) psychiatric disease , endstage disease state , disease could interfere conduct validity study compromise subject safety ; Have know concurrent temporary secondary cause AF alcohol intoxication , pulmonary embolism , hyperthyroidism , pneumonia , hypoxemia ( oxygen saturation &lt; 90 % room air ) , acute pericarditis , myocarditis ; Potassium ( K+ ) &lt; 3.5 mmol/L &gt; 5.5 mmol/L magnesium ( Mg2+ ) low limit normal ( Mg2+ &lt; 0.65 mmol/L subject 65 year young &lt; 0.80 mmol/L subject 66 year old ) . ( Both K+ Mg2+ correct prior dose ) ; Have clinical evidence digoxin toxicity ; Have receive oral Class I Class III antiarrhythmic agent ( include sotalol ) within 3 day randomisation oral amiodarone within 4 week , receive intravenous Class I Class III antiarrhythmic agent i.v . amiodarone within 24 hour prior start dose ; Have surgical medical condition , judgment clinical Investigator might warrant exclusion contraindicate safety reason ; Be concurrently participate another drug study receive investigational drug within 30 day prior screen ; Be unable communicate well Investigator comply requirement entire study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Atrial Fibrillation</keyword>
</DOC>